Related Experiment Video
Updated: Apr 26, 2026
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review)
Björn Georgi1, Nina Korzeniewski2, Boris Hadaschik1
1Department of Urology, University of Heidelberg School of Medicine, D-69120 Heidelberg, Germany.
Abstract:
Treatment of castration resistant prostate cancer (CRPC) continues to represent a major urooncological challenge due to tumor heterogeneity and the inevitable development of therapy resistance. Although androgen deprivation therapy retains an important role in the management of CRPC, recent evidence suggests that a broader spectrum of therapeutic targets may improve patient response and delay development of advanced disease. Genome-wide analyses have identified four major signaling nodes that are most frequently altered in prostate cancer: i) the androgen receptor (AR); ii) the PI3K pathway; iii) the Ras/Raf/MEK/ERK pathway; and iv) the retinoblastoma protein (pRB) signaling pathway. Extensive crosstalk and redundancy exists between these signaling pathways, which underscores the need for combination therapies. There are several novel AR pathway inhibitors currently in clinical use. Clinical trials are being performed on single-agent PI3K inhibitors with some success in tumors with genetically altered PI3K components. MEK/ERK inhibitors are also in clinical trials and the importance of pRB inactivation in prostate cancer is becoming more widely recognized. A greater understanding of the effects of single agent therapy on compensatory signaling pathway activation that can potentially thwart antitumoral responses is urgently needed and will provide additional insight into the mechanism of therapy resistance and how to further delay the progression to lethal disease.
Insights
Treating castration resistant prostate cancer (CRPC) is challenging due to resistance. Targeting multiple signaling pathways like androgen receptor (AR), PI3K, and Ras/Raf/MEK/ERK may improve patient outcomes and delay disease progression.
Area of Science:
- Urooncology
- Cancer Signaling Pathways
- Prostate Cancer Therapeutics
Background:
- Castration-resistant prostate cancer (CRPC) presents significant treatment challenges due to tumor heterogeneity and therapy resistance.
- Androgen deprivation therapy is a cornerstone of CRPC management, but novel therapeutic targets are needed to improve responses and delay advanced disease.
- Genome-wide analyses reveal four key signaling pathways frequently altered in prostate cancer: androgen receptor (AR), PI3K, Ras/Raf/MEK/ERK, and retinoblastoma protein (pRB).
Purpose of the Study:
- To review the current landscape of therapeutic targets in CRPC.
- To highlight the importance of targeting multiple signaling pathways due to crosstalk and redundancy.
- To emphasize the need for further research into combination therapies and understanding resistance mechanisms.
Main Methods:
- Review of current clinical evidence and genome-wide analyses of prostate cancer signaling pathways.
- Analysis of novel therapeutic agents targeting AR, PI3K, and MEK/ERK pathways.
- Discussion of the role of pRB signaling in prostate cancer progression.
Main Results:
- Novel androgen receptor (AR) pathway inhibitors are in clinical use.
- Single-agent PI3K inhibitors show some success in genetically altered tumors.
- MEK/ERK inhibitors are under clinical investigation, and pRB inactivation is increasingly recognized.
Conclusions:
- Crosstalk and redundancy among AR, PI3K, Ras/Raf/MEK/ERK, and pRB pathways necessitate combination therapies for CRPC.
- Understanding compensatory signaling activation is crucial for overcoming therapy resistance.
- Further research is needed to delay the progression of lethal prostate cancer.
More Related Videos
07:34Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
Published on: November 17, 2023
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019